Fortress Biotech Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Fortress Biotech Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- FBIO
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001429260
Board of directors
-
Dov Klein · DirectorSince 2023
-
Eric K. Rowinsky · DirectorSince 2023
-
J. Jay Lobell · DirectorSince 2023
-
Jimmie Harvey · DirectorSince 2023
-
Kevin Lorenz · DirectorSince 2023
-
Lindsay A. Rosenwald M.D. · Director · PRESIDENT, CEO & CHAIRMANSince 2023
-
Lucy Lu · DirectorSince 2023
-
Malcolm Hoenlein · DirectorSince 2023
-
Michael S. Weiss · Director · Executive Vice ChairmanSince 2023
Chief executives
Lindsay A. Rosenwald M.D.
· President, CEO & Chairman
Dates unknown
Board connections
4 of this board's directors also sit on 6 other boards.
- via Lindsay A. Rosenwald M.D. and Michael S. Weiss
- via Eric K. Rowinsky
- via Lindsay A. Rosenwald M.D.
- via Michael S. Weiss
- via Eric K. Rowinsky
- via Lucy Lu
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jan 1, 2025 | J. Jay Lobell Director | Grant or award | +49,383 | — | — |
| Jan 1, 2025 | Dov Klein Director | Grant or award | +49,383 | — | — |
| Jan 1, 2025 | Lucy Lu Director | Grant or award | +49,383 | — | — |
| Jan 1, 2025 | Jimmie Harvey Director | Grant or award | +49,383 | — | — |
| Jan 1, 2025 | Kevin Lorenz Director | Grant or award | +49,383 | — | — |
| Jan 1, 2025 | Malcolm Hoenlein Director | Grant or award | +49,383 | — | — |
| Jan 1, 2025 | Michael S. Weiss Director, Officer (Executive Vice Chairman) | Grant or award | +454,153 | — | — |
| Jan 1, 2025 | Lindsay A. Rosenwald M.D. Director, Officer (PRESIDENT, CEO & CHAIRMAN), 10% owner | Grant or award | +454,153 | — | — |
| Dec 19, 2024 | David Jin Officer (Chief Financial Officer) | Grant or award | +1,000,000 | — | — |
| Oct 1, 2024 | David Jin Officer (Chief Financial Officer) | Grant or award | +2,625 | $1.23 | $3,229 |
| Sep 23, 2024 | Lindsay A. Rosenwald M.D. Director, Officer (PRESIDENT, CEO & CHAIRMAN), 10% owner | Open-market purchase | +763,359 | $1.84 | $1,404,581 |
| Jul 11, 2024 | Lindsay A. Rosenwald M.D. Director, Officer (President, CEO & Chairman), 10% owner | Open-market purchase | +5,000 | $7.48 | $37,400 |
| Jul 10, 2024 | Jin David Officer (Chief Financial Officer) | Open-market purchase | +500 | $7.50 | $3,750 |
| Jul 9, 2024 | Lindsay A. Rosenwald M.D. Director, Officer (President, CEO & Chairman), 10% owner | Open-market purchase | +5,000 | $7.39 | $36,950 |
| Jul 8, 2024 | Lindsay A. Rosenwald M.D. Director, Officer (President, CEO & Chairman), 10% owner | Open-market purchase | +5,000 | $7.35 | $36,750 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.